

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Claim 1. (withdrawn).

Claim 2. (currently amended) A DNA encoding a bifunctional protein, wherein said protein comprises :

- (i) an antigen binding domain derivable from an anti-ErbB2 antibody;
- (ii) a hinge region comprising from about 40 to about 200 amino acids, and
- (iii) a functional zeta ( $\zeta$ ) chain derivable from the T-cell antigen receptor (TCR);  
wherein the hinge region couples the antigen binding domain to the functional zeta chain.

Claim 3. (currently amended) A DNA according to claim 2 encoding a protein wherein the antigen binding domain is a sequence produced by a hybridoma cell line having a deposit number selected from the group consisting of 90112115, 90112116, 90112117, and 90112118 FRP5 (scFv(FRP5)).

Claim 4. (previously presented) A DNA according to claim 2 encoding a protein wherein the hinge region is from an immunoglobulin-like protein.

Claim 5. (currently amended) A DNA according to claim 2 encoding a protein wherein the functional zeta ( $\zeta$ ) chain comprises the transmembrane and the cytoplasmic domain of the zeta chain.

Claim 6. (previously presented) A host cell expressing the DNA claim 2.

Claim 7. (previously presented) A host cell according to claim 6 which is a cytotoxic lymphocyte (CTL).

Claim 8. (withdrawn).

Claim 9. (currently amended) A process for endowing a CTL with a defined, MHC-independent and MHC-unrestricted tumor cell specifically comprising introducing into said CTL a the DNA according to of claim 2.

Claim 10. (currently amended) A method for the production of a bifunctional protein according to claim 1 comprising: culturing a host cell ~~of~~ containing DNA encoding said protein under conditions which allow the expression of a protein encoded by the DNA of claim 2; and removing bifunctional protein from the host cell culture encoding said protein.

Claim 11. (previously presented) A composition-of-matter comprising a host cell according to claim 7.

Claim 12. (withdrawn).

Claim 13. (currently amended) ~~CTL according to claim 7 for use in a~~ A method of treating cancer, comprising contacting the cancer with CTL that expresses the DNA described in claim 2.

Claim 14. (withdrawn).

Claim 15. (previously presented) Vector comprising a DNA according to claim 2.